Chronic kidney disease (CKD) refers to the gradual loss of kidney function over time. It is a major global public health problem affecting 1 in 10 people worldwide. The main functions of kidneys are removing waste and excess fluid from the blood and balancing electrolytes and minerals like sodium, potassium, and calcium. When kidneys are damaged or diseased, they don't function properly causing waste to build up in the blood. Common symptoms include feeling tired and weak, changes in urination, swelling of legs and face. CKD drugs aim to slow down the progression of loss of kidney function, reduce risks of associated health issues like anemia, bone disease, heart disease and improve quality of life. Key drugs include erythropoiesis-stimulating agents, calcium channel blockers and angiotensin-converting enzyme inhibitors. The rising prevalence of diabetes and hypertension which are leading causes of CKD is driving the demand for better and effective treatment options.

The global chronic kidney disease drugs market is estimated to be valued at US$ 15086.22 Mn in 2024 and is expected to exhibit a CAGR of 4.5% over the forecast period 2024 to 2031

Key Takeaways

Key players operating in the chronic kidney disease drugs market are Sanofi, AstraZeneca plc., Amgen, Inc., Regeneron Pharmaceuticals, Inc., AbbVie Inc., ProKidney Corp., Pfizer, Inc., Bayer AG, F. Hoffmann-La Roche AG, Kissei Pharmaceutical Co., Ltd., Reata Pharmaceuticals, Inc., GlaxoSmithKline plc., Ardelyx, Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Novartis AG, Johnson and Johnson, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Kibow Biotech, Inc., FibroGen, Inc., Cara Therapeutics, Pieris Pharmaceuticals, Inc., Mitsubishi Chemical Group Corporation, Pharmacosmos A/S., OPKO Health, Inc., Covis Pharma, Tricida, Inc., Eli Lilly and Company, Biosidus S.A., Teva Pharmaceutical Industries Ltd., YUHAN, Caladrius Biosciences, Inc., UnicoCell Biomed CO. LTD, Akebia Therapeutics, Inc., Allena Pharmaceuticals, and KBP Biosciences Co., Ltd. Key opportunities lie in developing combination therapies, better diagnostic tools and new drug targets like G protein-coupled receptors. Technological advancements are focused on gene therapy, stem cell therapy and regenerative medicine approaches to repair or replace damaged kidneys.

Market Drivers

The increasing prevalence of chronic kidney disease as a result of diabetes, hypertension and obesity is a major growth driver. It is estimated that over 1 in 7 people worldwide have some form of CKD. The rising geriatric population who are more prone to these conditions is another demand influencing factor. Growing awareness about early detection of CKD and availability of various reimbursement schemes for kidney disease treatment is propelling the market forward. Robust research and development activities to come up with

Current challenges in Chronic Kidney Disease Drugs Market

Chronic Kidney Disease Drugs Market Demand has emerged as a global public health concern. As per estimates, approximately 10-15% of the world's population is living with some stage of CKD. However, the lack of awareness about the early symptoms of CKD remains a key challenge. Most patients experience advanced stages of the disease before being diagnosed, limiting treatment options and impacting long-term outcomes. Moreover, CKD disproportionately burdens underprivileged populations who have limited access to quality healthcare services. Affordability of treatment also poses a major barrier, considering the need for lifelong management through medications and monitoring. On the drug development front, discovering safer and more effective therapeutic agents against CKD progression has proven to be challenging due to the complexity of the disease pathology. More research efforts are thus needed to expedite the development of novel drugs targeting specific pathways of kidney injury and repair.

SWOT Analysis
Strength: Growing R&D investments by major players to develop innovative treatment solutions. Weakness: High unmet medical needs due to lack of complete cure and high cost of management. Opportunity: Rising CKD patient pool worldwide drives market potential. Threats: Stringent regulations for drug approval and side effects associated with long-term medication intake.

Geographically, North America is expected to dominate the global chronic kidney disease drugs market during the forecast period. This is majorly attributed to the rising prevalence of diabetes and hypertension as primary risk factors for CKD in the region. Favorable reimbursement policies for CKD medications in countries such as the US and Canada also support market growth.
Asia Pacific is projected to witness the fastest growth over the coming years, led by China and India. Factors such as the massive patient population, improving access to healthcare, and increasing government focus on strengthening renal care infrastructure will boost regional market revenues.

Get more insights on Chronic Kidney Disease Drugs Market

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)